Comprehensive Inpatient Cardiology Care Plan

A structured hospital care plan for cardiology patients should prioritize systematic assessment, evidence-based pharmacotherapy, continuous monitoring, patient education, and coordinated discharge planning to reduce mortality and readmission rates.

Initial Assessment and Risk Stratification

Upon admission, establish a comprehensive baseline assessment within the first 24 hours:

Diagnostic Workup

ECG and cardiac biomarkers (troponin, natriuretic peptides) to confirm diagnosis and assess severity 1, 2
Echocardiography to evaluate left ventricular function, ejection fraction, and determine etiology 2
Laboratory monitoring: Daily measurement of renal function (creatinine, urea), electrolytes (particularly potassium), and liver function 2, 3
Natriuretic peptide levels (BNP/NT-proBNP) for diagnostic confirmation and prognostic stratification 2

Clinical Assessment Components 2

Establish heart failure diagnosis and presenting features (pulmonary edema, dyspnea, peripheral edema)
Assess symptom severity using NYHA classification
Determine underlying etiology
Identify precipitating factors (medication non-adherence, dietary indiscretion, arrhythmias, infection)
Document concomitant diseases affecting management
Estimate prognosis and anticipate complications
Designate surrogate decision maker 4

Pharmacological Management

First-Line Therapy for Heart Failure

ACE Inhibitors - Foundation of treatment 2:

Start after stabilizing fluid status; may withhold diuretics 24 hours before initiation
Begin with low dose, preferably in evening when supine to minimize hypotension
Titrate every 1-2 weeks to target doses from clinical trials
Monitor blood pressure, renal function, and electrolytes at 1-2 weeks after each dose increase, then at 3 months, then every 6 months
Avoid NSAIDs and potassium-sparing diuretics during initiation 2

Diuretics - Essential for symptomatic relief 2:

Loop diuretics or thiazides for initial treatment (always with ACE inhibitor)
If GFR <30 mL/min, avoid thiazides except synergistically with loop diuretics
For insufficient response: increase dose, combine loop diuretics with thiazides, or administer loop diuretics twice daily
In severe cases, add metolazone with frequent creatinine/electrolyte monitoring 2

Beta-Blockers - Mortality reduction in stable patients 2:

Initiate only when patient is relatively stable, on ACE inhibitor background therapy, without IV inotrope need or marked fluid retention
Start very low dose, double every 1-2 weeks if tolerated
Monitor for worsening heart failure, fluid retention, hypotension, bradycardia
If symptoms worsen: increase diuretics/ACE inhibitor first, temporarily reduce beta-blocker only if necessary
Never abruptly discontinue - always attempt reintroduction when stable 2

Aldosterone Antagonists (Spironolactone) - For advanced heart failure 2:

Indicated for NYHA class III-IV in addition to ACE inhibitor and diuretics
Start 25 mg daily if serum potassium ≤5.0 mmol/L and creatinine ≤250 μmol/L
Check potassium and creatinine after 4-6 days
Stop if potassium ≥5.5 mmol/L; reduce dose by 50% if potassium 5.5-6.0 mmol/L
May increase to 50 mg daily after 1 month if symptoms persist and normokalemia maintained 2

Additional Pharmacotherapy

Digoxin 2:

For atrial fibrillation with any degree of heart failure to control ventricular rate
In sinus rhythm: for persistent symptoms despite ACE inhibitor and diuretic treatment
Dose: 0.25-0.375 mg daily (normal renal function); 0.125-0.25 mg in elderly
No loading dose needed for chronic conditions
Contraindications: bradycardia, 2nd/3rd-degree AV block, sick sinus syndrome, hypokalemia, hypercalcemia

ARBs (Angiotensin Receptor Blockers) 2:

Consider for ACE inhibitor-intolerant patients (significantly less cough)
May combine with ACE inhibitor to reduce hospitalizations, though mortality benefit unclear

Continuous Monitoring Protocol 3

Daily Requirements

Weight measurement with accurate fluid balance charting
Vital signs: pulse, respiratory rate, blood pressure (standard noninvasive monitoring)
Renal function and electrolytes measured daily during active diuresis
Clinical assessment for signs of congestion, hypoperfusion, medication side effects

Hemodynamic Stability Criteria

Avoid routine invasive hemodynamic monitoring except in cardiogenic shock or refractory cases 2
For cardiogenic shock: SBP <90 mmHg with signs of hypoperfusion (oliguria, cold peripheries, altered mental status, lactate >2 mmol/L) 3

Patient Education and Self-Management 2

Provide structured education before discharge addressing:

Disease Understanding

What heart failure is and why symptoms occur
Specific causes of their heart failure
How to recognize worsening symptoms
When and how to seek help
Importance of daily self-weighing

Medication Adherence

Rationale for each medication
Critical importance of adherence to pharmacological prescriptions
How to manage side effects

Lifestyle Modifications

Sodium restriction (particularly in severe heart failure)
Fluid restriction in severe cases
Avoid excessive alcohol
Smoking cessation with nicotine replacement if needed
Exercise: daily physical activity encouraged in stable patients (not bed rest)
Travel considerations (avoid high altitudes, hot humid climates with severe HF)

Discharge Criteria and Planning 3

Patients are medically fit for discharge when:

Hemodynamically stable for at least 24 hours
Euvolemic (no signs of congestion)
Established on evidence-based oral medications
Stable renal function for ≥24 hours
Completed tailored education

Post-Discharge Follow-Up Structure 3

General practitioner visit: within 1 week of discharge
Cardiology follow-up: within 2 weeks of discharge
Telephone follow-up: within 3 days of discharge
Enrollment in multidisciplinary heart failure disease management program
Pre-discharge natriuretic peptide measurement for risk stratification (lower levels predict better outcomes) 3

Discharge Documentation 4

Create focused discharge handoff including:

Optimized medication regimen with clear titration plan
Rescue diuretic dosing instructions with specific triggers
Weight monitoring thresholds for intervention
Emergency contact information
Follow-up appointment schedule

Specialist Referral Criteria 2

Refer to specialist care for:

Severe heart failure (NYHA class III/IV)
Unknown etiology requiring advanced diagnostics
Relative contraindications to beta-blockers (bradycardia, low blood pressure)
Intolerance to low-dose beta-blockade
Previous beta-blocker discontinuation due to symptoms
Suspected asthma or bronchial disease
Consideration for advanced therapies (transplant, mechanical support)

Special Considerations

Atrial Fibrillation Management 2

Rate control mandatory in permanent AF
Digoxin first choice in symptomatic patients
Beta-blockers or combination therapy in asymptomatic patients
Consider electrical cardioversion for persistent AF (success depends on duration and left atrial size)

Concomitant Angina or Hypertension 2

Optimize existing beta-blockade
Consider coronary revascularization if angina present
Add long-acting nitrates if needed
For persistent hypertension: optimize ACE inhibitor, beta-blocker, diuretic doses; add spironolactone or ARB; consider second-generation dihydropyridines if unsuccessful

Quality Improvement Measures

Key performance indicators to monitor 5, 6:

30-day readmission rates (target <10%)
One-year mortality
Adherence to guideline-directed medical therapy at discharge
Time to follow-up appointments
Patient education completion rates

Critical success factors 5:

Well-defined treatment procedures
Enhanced multidisciplinary communication and teamwork
Adequate hospitalization duration (minimum 5 days for optimization)
Structured post-discharge follow-up
Use of NT-proBNP for treatment response assessment

This structured approach, when implemented systematically, has demonstrated significant reductions in 30-day readmission rates (from 30% to 5%) and one-year mortality (from 34% to 18%) 5.

What is a comprehensive inpatient cardiology care plan?

Have a follow-up question?